CogState Limited shares fall on profit guidance update

This afternoon cognitive testing business CogState Limited (ASX: CGS) warned investors financial results for FY 2018 and FY 2019 will be weaker-than-expected due to the recent termination of Alzheimer’s disease trials by its customers.

Over the quarter to June 30 2018 CogState reported a cash outflow of $1.3 million, although it did flag a corresponding increase in receivables of $1.1 million over the quarter.

For the full year it posted a cash outflow of $2.46 million on revenue of $29 million, with revenue growth clocking in at 9.6% over FY 2017.

CogState also reported that it has a “contracted revenue backlog of $34.8 million at 30 June 2018 to be recognised in FY 19 and beyond”.

As at 30 June 2018 it had $4.4 million cash on hand, which suggests the balance sheet is in reasonable shape.

This is a mixed update as while revenue growth is reasonable the business also appears to be growing costs and the news around the cancelled Alzheimer’s trials is a concern for a business that’s core operational performance metric remains the provision of cognitive clinical trials services.

It was only recently trumpeting the deal to support all Alzheimer’s clinical trials for pharmaceutical giant, Eli Lilly, however, the trials’ potential winding back based on today’s news is likely behind the near 10% falls in the share price to 71 cents.

CogState is due to hand in its full year profit report to the market on August 13, where more details will be provided over profit guidance for FY 2019.

The Disruptors: 3 Revolutionary Aussie Companies to Back for 2018

We’re living in one of the most exciting times in investing history. Innovation and a booming culture of entrepreneurship are constantly creating new companies with the potential to make forward-thinking investors very rich. Now more than ever, one small, smart investment could make a huge difference to your wealth.

That’s why at The Motley Fool we’ve been scrutinizing the ASX to uncover the kinds of companies that we believe could turn into the next Atlassian.

We’ve found three exciting companies that we believe re poised to perform in the new year. Click here to uncover these ideas!

Motley Fool contributor Tom Richardson has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Two New Stock Picks Every Month!

Not to alarm you, but you’re about to miss a very important event! Chief Investment Advisor Scott Phillips and his team at Motley Fool Share Advisor are about to reveal their latest official stock recommendation. The premium “buy alert” will be unveiled to members and you can be among the first to act on the tip.

Don’t let this opportunity pass you by – this is your chance to get in early!

Simply enter your email now to find out how you can get instant access.

By clicking this button, you agree to our Terms of Service and Privacy Policy. We will use your email address only to keep you informed about updates to our website and about other products and services we think might interest you. You can unsubscribe from Take Stock at anytime. Please refer to our Financial Services Guide (FSG) for more information.